RGC Regencell Bioscience Holdings Limited
Healthcare$25.80-4.44%ClosedMarket Cap: $12.76B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
10462.52
P/S
0.00
EV/EBITDA
-1814.43
DCF Value
$0.00
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-231.9%
ROA
-233.9%
ROIC
-444.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $0.00 | -Infinity% | $-5.3M | $-5.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.8M | $-1.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-3.8M | $-3.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.0M | $-1.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.2K | $-1.1K | $— | — |
| FY null | $0.00 | -Infinity% | $-4.7M | $-4.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.2K | $-1.0K | $— | — |
| Q4 null | $0.00 | -Infinity% | $-2.8M | $-2.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-6.3M | $-5.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.4M | $-3.2M | $— | — |
| Q4 null | $-2.34B | 100.0% | $-4.0M | $-3.9M | $— | — |
| FY null | $0.00 | -Infinity% | $-7.6M | $-7.4M | $— | — |